To: ghmm who wrote (430 ) 10/4/2018 9:59:52 PM From: Miljenko Zuanic Respond to of 507 <Though its certainly lacking management has given an explanation (the data need to mature). Whether that proves accurate or management can be trusted is a different issue.> Do you know how many pts from those 3/15 and 5/15 already have PD (dropped out) and what MATURITY means for overall data! Maturity will not bring "RELIEF" for overall results, but "EXPLANATION", if they have one, will/may help in projecting 214 value. Bios investing is nothing more than "PROJECTING", or in plain language....PUMP-and-DUMP. Like it or not, it is all "Pump-and-Dump! None can give you correct projection. NONE! Instead "reliefing' investor from anxiety (at least me), they are awarding (board and exec) with options and free stocks (based on 181???). Great approach! How can you talk about OTHER INDICATION, .....when it is all about synergy with IO. IF does not work for "A", what mode of action can explain.... working for "B"??? It has to work with CLASS COMPOUND(S), not ...other indication(S). Yes, some cancer type is harder to treat than other,....but it is combo approach...where mono-agent work well...214 combo will work even better! Simple than that can not be! Maybe where mono-IO has marginal activity combination with 214 will increase level to significant...but that all would be secondary indications, down the road. So, do not be afraid to ask question where question is warranted,...many like to agree with "majority". I like to be opposition...sometimes not popular, ,,,but one way to find true is to put on "other" shoes! All this simple put...IL-2 is (IMO) "chain loop" in immunology. Broken loop is broken chain..... Fix the loop/link.... restore chain!